Agendia, a developer of genomic-based diagnostic products, has unveiled ColoPrint microarray-based 18-gene expression signature.
The ColoPrint assay provides critical additional information for treatment decisions for stage II colon cancer patients who have undergone surgery.
ColoPrint also helps in eliminating the gray area of indeterminate results found in 70% of patients, using clinical and pathologic factors such as T4-stage and Microsatellite Instability status.
Agendia CEO David Macdonald said, "ColoPrint's definitive results (either high or low risk with no in between) will enable doctors to choose treatment plans for colon cancer patients that are customized for each patient's individual needs."